Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

The benefit-risk profile of finerenone (Kerendia) for heart failure and mildly reduced or preserved ejection fraction (HFmrEF ...

Sanofi and Regeneron have announced that dupilumab has received FDA approval as an add-on maintenance treatment for adults ...

Regeneron’s gene therapy for otoferlin-related ... so somewhat ironic that the FDA has just authorised software that can turn Apple AirPods into hearing aids. In the age of AI, large data ...

The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...

USA Today reports on how the former president benefitted after a diagnosis that just years prior would have been terminal. Cancer therapies have enabled him to celebrate his 100th birthday this week.

Modalis Therapeutics has been awarded a rare paediatric disease designation by the US Food and Drug Administration (FDA) for ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...

Barclays analyst Carter Gould maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,220.00.

SK pharmteco, a contract development and manufacturing organisation, has announced an investment of $260m to expand its small ...

China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...

Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...